ReviewFrontiers in pharmacology2026
Molecularly engineered BODIPY photosensitizers for combined cancer phototherapy and immunotherapy.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BODIPY-based photosensitizers have attracted great interest in cancer phototherapy and immunotherapy due to their tunable structures, excellent photostability, and high molar extinction coefficients. However, conventional BODIPY dyes have inherent limitations, such as poor water solubility, shallow tissue penetration, oxygen dependence, and insufficient single-modality efficacy. To address these, recent studies have used molecular engineering (ring fusion, electronic modulation, supramolecular assembly, metal coordination) to enhance reactive oxygen species generation and photothermal conversion. Smart delivery systems with microenvironment responsiveness further enable tumor targeting and microenvironment remodeling. Importantly, BODIPY-mediated phototherapy combined with immunotherapeutic strategies (immune checkpoint blockade, pyroptosis/cuproptosis induction, cGAS-STING activation, etc.) achieves synergistic antitumor effects, transforming localized tumor ablation into systemic immunity. This review summarizes recent progress in molecularly engineered BODIPY photosensitizers, from molecular optimization and smart delivery to immune synergy, and discusses current challenges and future directions to promote their clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.